Dilon Technologies Partners With PenRad Mammography Information Systems to Provide Streamlined Diagnostic Analysis and Reporting
NEWPORT NEWS, Va., Nov. 6 /PRNewswire/ -- Dilon Technologies announced
today that they have entered into a co-marketing partnership with PenRad
Mammography Information Systems. Dilon will introduce the PenRad system to its
Dilon 6800 Gamma Camera customers as a tool to effectively streamline patient
exam analysis and reporting.
The Dilon 6800 Gamma Camera is a high-resolution, small field-of-view
gamma camera, optimized to perform Breast-Specific Gamma Imaging (BSGI), a
molecular breast imaging procedure that images the metabolic activity of
breast lesions through radiotracer uptake. The PenRad MIS auditing and
tracking system creates efficiencies for clinics and hospitals where BSGI is
performed. The software helps facilities meet MQSA requirements by creating
reports, patient letters, statistics, analytics, and more. PenRad's unique
design benefits the patient, technologist, radiologist and administrative
office personnel, increasing the productivity and profitability of a practice.
"This alliance is a natural extension to our Dilon 6800 Gamma Camera and
BSGI offering to the physician," said Bob Moussa, President and CEO of Dilon
Technologies. "With the PenRad system, our customers can save time, increase
efficiency and ease workflow when using BSGI."
BSGI is a molecular breast imaging technique that can see lesions
independent of tissue density and discover very early stage cancers. BSGI
serves as a complementary diagnostic adjunct procedure to mammography and
ultrasound for difficult-to-diagnose patients. With BSGI, the patient receives
a pharmaceutical tracing agent that is absorbed by all the cells in the body.
Due to their increased rate of metabolic activity, cancerous cells in the
breast absorb a greater amount of the tracing agent than normal, healthy cells
and generally appear as "hot spots" on the BSGI image.
"Molecular imaging using BSGI has become an important tool in the quest
for early diagnosis of breast cancer," said Greg Gustafson, President of
PenRad. "We are excited to partner with Dilon so we can help advance patient
care efficiently on the management information side."
Dilon will feature the PenRad alliance at the Radiological Society of
North America 2008 annual meeting in Chicago, November 30 through December 5.
About PenRad
PenRad Technologies, headquartered in Minnetonka, Minnesota, continues to
be the leader in providing advanced Mammography Management System technology
to simplify and enhance viewing, reporting and audit tracking to ensure breast
imaging centers can function at the highest level of efficiency and accuracy,
and easily conform to all FDA, MQSA and HIPAA requirements. For more
information, visit http://www.penrad.com.
About Dilon Technologies
Dilon Technologies Inc. is bringing innovative new medical imaging
products to market. Dilon's cornerstone product, the Dilon 6800, is a
high-resolution, small field-of-view gamma camera, optimized to perform BSGI,
a molecular breast imaging procedure which images the metabolic activity of
breast lesions through radiotracer uptake. Many leading medical centers around
the country are now offering BSGI to their patients, including: Cornell
University Medical Center, New York; George Washington University Medical
Center, Washington, D.C.; and The Rose, Houston. For more information on Dilon
Technologies please visit http://www.dilon.com.
